aod9604 administration method AOD 9604 Peptide AOD 9604 Peptide for Fat

human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal

[5] In the same 28-day study, DIO mice showed reduced body weight and fat mass gains alongside improved glucose tolerance and attenuated hepatic steatosis

Allergic reactions are possible, though infrequent

Status Not FDA-approved